title: Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma.
abstract: BACKGROUND
  The subtypes of NSCLC have unique characteristics of pathogenic mechanism and responses to targeted therapies. Thus, non-invasive markers for diagnosis of different subtypes of NSCLC at early stage are needed.
  
  
  RESULTS
  Based on the results from the screening and validation process, 3 miRNAs (miR-532, miR-628-3p and miR-425-3p) were found to display significantly different expression levels in early-stage lung adenocarcinoma, as compared to those in healthy controls. ROC analysis showed that the miRNA-based biomarker could distinguish lung adenocarcinoma from healthy controls with high AUC (0.974), sensitivity (91.5%), and specificity (97.8%). Importantly, these three miRNAs could also distinguish lung adenocarcinoma from lung benigh diseases and other subtypes of lung cancer.
  
  
  METHODS
  Two hundreds and one early-stage lung adenocarcinoma cases and one hundreds seventy eight age- and sex-matched healthy controls were recruited to this study. We screened the differentially expressed plasma miRNAs using TaqMan Low Density Arrays (TLDA) followed by three-phase qRT-PCR validation. A risk score model was established to evaluate the diagnostic value of the plasma miRNA profiling system.
  
  
  CONCLUSIONS
  Taken together, these findings suggest that the 3 miRNA-based biomarker might serve as a novel non-invasive approach for diagnosis of early-stage lung adenocarcinoma.
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.|National Clinical Research Center of Cancer, 300060 Tianjin, China.|Key Laboratory of Cancer Immunology and Biotherapy, 300060 Tianjin, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.|National Clinical Research Center of Cancer, 300060 Tianjin, China.|Key Laboratory of Cancer Immunology and Biotherapy, 300060 Tianjin, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.|National Clinical Research Center of Cancer, 300060 Tianjin, China.|Key Laboratory of Cancer Immunology and Biotherapy, 300060 Tianjin, China.
authors.forename: Xujie
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.|National Clinical Research Center of Cancer, 300060 Tianjin, China.|Key Laboratory of Cancer Immunology and Biotherapy, 300060 Tianjin, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wei
authors.affiliation: Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.|National Clinical Research Center of Cancer, 300060 Tianjin, China.|Key Laboratory of Cancer Immunology and Biotherapy, 300060 Tianjin, China.
authors.forename: Xinwei
authors.initials: X
authors.lastname: Zhang
authors.affiliation: National Clinical Research Center of Cancer, 300060 Tianjin, China.|Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Su
authors.affiliation: National Clinical Research Center of Cancer, 300060 Tianjin, China.|Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.
authors.forename: Changli
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.|National Clinical Research Center of Cancer, 300060 Tianjin, China.|Key Laboratory of Cancer Immunology and Biotherapy, 300060 Tianjin, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, 300060 Tianjin, China.|National Clinical Research Center of Cancer, 300060 Tianjin, China.|Key Laboratory of Cancer Immunology and Biotherapy, 300060 Tianjin, China.
authors.forename: Xiubao
authors.initials: X
authors.lastname: Ren
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D016022:Case-Control Studies; D055088:Early Detection of Cancer; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs
keywords: biomarker; diagnosis; lung adenocarcinoma; miRNA; plasma